文献速递肝病

代谢功能障碍相关脂肪性肝病与心脏

Metabolic dysfunction-associated steatotic liver disease and the heart.
PubMed 文献 · Hepatology · 2023-12-25

该综述梳理代谢功能障碍相关脂肪性肝病(MASLD)与心脏病的相互关系。流行病学研究显示MASLD患者动脉粥样硬化增加,但动脉粥样硬化性心血管疾病死亡风险未增加;两者共享肥胖、胰岛素抵抗、2型糖尿病、吸烟、高血压和睡眠呼吸暂停等驱动因素;孟德尔随机化研究支持MASLD可能通过混合型高脂血症导致动脉粥样硬化。鉴于心血管事件发生率增加,MASLD患者需全面的心血管代谢风险管理,最好采用多学科方法。

要点

  • MASLD与动脉粥样硬化性心血管疾病共享肥胖、胰岛素抵抗、2型糖尿病、吸烟、高血压和睡眠呼吸暂停等驱动因素。
  • MASLD患者动脉粥样硬化增加,但动脉粥样硬化性心血管疾病死亡风险未增加。
  • MASLD患者需全面的心血管代谢风险管理,最好采用多学科方法。

核心结论

  • 鉴于MASLD与动脉粥样硬化性心血管疾病强共现、共享驱动因素、潜在因果因素,尤其心血管事件发生率增加,MASLD患者需全面的心血管代谢风险管理,最好采用多学科方法。

研究设计与样本

  • 综述,总结MASLD与心脏病相互关系的流行病学研究、孟德尔随机化研究及治疗相关证据。

主要发现

  • 评估动脉粥样硬化替代指标和实际心血管事件的流行病学研究表明MASLD患者动脉粥样硬化增加,但动脉粥样硬化性心血管疾病死亡风险未增加。
  • MASLD与动脉粥样硬化性心血管疾病共享肥胖、胰岛素抵抗、2型糖尿病、吸烟、高血压和睡眠呼吸暂停综合征等驱动因素。
  • 孟德尔随机化研究支持MASLD可能通过混合型高脂血症导致动脉粥样硬化,而肝脏来源促凝因子的此类证据缺乏。
  • 在更晚期纤维化阶段,MASLD可能通过右心室充盈减少导致射血分数保留的心力衰竭,后者可引起劳力性疲劳,MASLD患者常提及此症状。
  • 一些证据提示MASLD与心律失常之间存在关联。

关键数值与推荐

  • MASLD与动脉粥样硬化性心血管疾病强共现,针对MASLD晚期阶段在研的药物治疗理想情况下也应减少心血管事件,正如2型糖尿病治疗已证实的那样。

临床怎么用

  • 鉴于MASLD与动脉粥样硬化性心血管疾病强共现、共享驱动因素和潜在因果因素,尤其心血管事件发生率增加,MASLD患者需全面的心血管代谢风险管理,最好采用多学科方法。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The prevalence and severity of metabolic dysfunction-associated steatotic liver disease (MASLD) are increasing. Physicians who treat patients with MASLD may acknowledge the strong coincidence with cardiometabolic disease, including atherosclerotic cardiovascular disease (asCVD). This raises questions on co-occurrence, causality, and the need for screening and multidisciplinary care for MASLD in patients with asCVD, and vice versa. Here, we review the interrelations of MASLD and heart disease and formulate answers to these matters. Epidemiological studies scoring proxies for atherosclerosis and actual cardiovascular events indicate increased atherosclerosis in patients with MASLD, yet no increased risk of asCVD mortality. MASLD and asCVD share common drivers: obesity, insulin resistance and type 2 diabetes mellitus (T2DM), smoking, hypertension, and sleep apnea syndrome. In addition, Mendelian randomization studies support that MASLD may cause atherosclerosis through mixed hyperlipidemia, while such evidence is lacking for liver-derived procoagulant factors. In the more advanced fibrotic stages, MASLD may contribute to heart failure with preserved ejection fraction by reduced filling of the right ventricle, which may induce fatigue upon exertion, often mentioned by patients with MASLD. Some evidence points to an association between MASLD and cardiac arrhythmias. Regarding treatment and given the strong co-occurrence of MASLD and asCVD, pharmacotherapy in development for advanced stages of MASLD would ideally also reduce cardiovascular events, as has been demonstrated for T2DM treatments. Given the common drivers, potential causal factors and especially given the increased rate of cardiovascular events, comprehensive cardiometabolic risk management is warranted in patients with MASLD, preferably in a multidisciplinary approach.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Driessen S, Francque SM, Anker SD, et al. Metabolic dysfunction-associated steatotic liver disease and the heart. Hepatology. 2023. PMID: 38147315. doi:10.1097/HEP.0000000000000735

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。